FedEx Cost Cuts and Upbeat Outlook Send Shares 14% Higher: 3 Other Reasons to BUY FDX
It had been a tough past few months for FedEX (FDX) investors, who watched their positions plummet 14%. But shares have recovered all that and more today after the delivery company released positive 4th quarter results for fiscal 2024. Earnings came in at $5.94 per share, which was ahead of the analyst expectation of $5.34 but lagged behind last [...]
Analysts are Bullish on IBM, But is it Actually Time to Buy This Stock? 3 Things to Consider First
Goldman Sachs analyst James Schneider helped send shares of International Business Machines (IBM) higher Monday with a bullish outlook on the company for the road ahead. He set a price target at $200 and says it’s time to buy this stock, which currently sits at $173. Schneider is bullish on the IT services segment in general, launching coverage on [...]
Should You Buy Chipotle (CMG) Ahead of the 50-for-1 Stock Split? 3 Things to Consider
The 50-for-1 stock split of Chipotle Mexican Grill (CMG) is scheduled to go live tomorrow (Tuesday, 6/25) after the market closes. As one of the largest stock splits in the history of the NYSE, all eyes are on the stock as the clock ticks down. Those who are new to the concept of stock splits may wonder what this [...]
Last Week’s Market Recap: Tech Gains and Mixed Results Define the Week
Monday: Tech Gains Propel Markets Higher Wall Street kicked off the week on a positive note, largely driven by strong performances in the technology sector. The Dow Jones Industrial Average climbed 0.5%, the S&P 500 rose by 0.8%, and the tech-heavy Nasdaq Composite led the pack with a 1.0% increase. The bullish sentiment in tech stocks helped outweigh some [...]
THE PRESIDENTIAL ELECTION CYCLE AND THE FED
Written by: Angela Akers As they have done for the last year, the Federal Reserve moved last week to leave interest rates unchanged at the elevated rate of 5.25% – 5.50% and signaled only one cut this year. That same morning, the May Consumer Price Index was released, coming in at a lower-than-expected increase of 3.3%. Additionally, Q1 earnings [...]
Sarepta Shoots up 36% on New Drug Breakthrough for DMD: 2 Reasons to Consider Buying SRPT
Sarepta Therapeutics (SRPT) announced late Thursday it had gained FDA approval for its treatment designed to target a rare genetic disease known as Duchenne muscular dystrophy (DMD). This condition causes progressive weakness, predominantly in boys, and is caused by a lack of key protein dystrophin. It has no known cure at this time. The typical protocol includes physical therapy [...]